|Bid||0.00 x 1300|
|Ask||0.00 x 1200|
|Day's Range||5.50 - 5.74|
|52 Week Range||4.41 - 10.30|
|Beta (5Y Monthly)||0.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jun 29, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.67|
Aurinia (AUPH) delivered earnings and revenue surprises of -13.64% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Here is how Alkermes (ALKS) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs today highlighted data from full patient enrollment in the pivotal Phase 3 SIERRA trial of Iomab-B was presented in an oral presentation at the upcoming Transplantation & Cellular Therapy (TCT) Tandem Meetings of ASTCT and CIBMTR, the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and